JPMorgan Healthcare Leaders ETF
JDOC
3 hedge funds and large institutions have $5.57M invested in JPMorgan Healthcare Leaders ETF in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3% less capital invested
Capital invested by funds: $5.75M → $5.57M (-$182K)
5.06% less ownership
Funds ownership: 75.49% → 70.44% (-5.1%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$352K |
| 2 |
IP
Ignite Planners
San Clemente,
California
|
-$35.8K |
JDOC Hedge Fund Activity: Q3 2024 in Review
3 of the 6,971 institutional investors tracked by Wall St. Rank reported a position in JPMorgan Healthcare Leaders ETF (JDOC) for Q3 2024, worth a combined $5.57M — down 3.2% from $5.75M a quarter earlier.
Fund positioning in JDOC was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.03K. The largest seller was Jane Street, exiting entirely with an estimated $352K sold.
- 3 institutional investors held JPMorgan Healthcare Leaders ETF (JDOC) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $5.57M of JPMorgan Healthcare Leaders ETF stock for Q3 2024, down 3.2% quarter-over-quarter.
- 1 fund opened new JPMorgan Healthcare Leaders ETF positions in Q3 2024 and 1 closed out, a net change of 0 holders.
- The largest JPMorgan Healthcare Leaders ETF buyer in Q3 2024 was UBS Group, an estimated $1.03K added.
- The largest JPMorgan Healthcare Leaders ETF seller in Q3 2024 was Jane Street, an estimated $352K sold.
Based on aggregated 13F filings for Q3 2024.